Circulating anandamide and blood pressure in patients with obstructive sleep apnea

Journal of Hypertension

Volumn 30, Issue 12, 2012, Pages 2345-2351

  Engeli, Stefan ^a   Blüher, Matthias ^b   Jumpertz, Reiner ^c   Wiesner, Tobias ^b   Wirtz, Hubertus ^b   Bosse Henck, Andrea ^b   Stumvoll, Michael ^b   Batkai, Sandor ^a   Pacher, Pal ^d   Harvey White, Judy ^d   Kunos, George ^d   Jordan, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

anandamide; endocannabinoid system; hypertension; obesity; sleep apnea; sympathetic nervous system

Indexed keywords

1 ARACHIDONOYLGLYCEROL; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; C REACTIVE PROTEIN; ENDOCANNABINOID; GLUCOSE; INSULIN; N OLEOYLETHANOLAMINE; UNCLASSIFIED DRUG;

ADULT; APNEA; ARTERIAL OXYGEN SATURATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN SENSITIVITY; LIQUID CHROMATOGRAPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SLEEP DISORDERED BREATHING; TANDEM MASS SPECTROMETRY;

EID: 84870250587     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283591595     Document Type: Article

References (27)

1. Romero-Corral A, Caples SM, Lopez-Jimenez F, Somers VK. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest 2010; 137:711-719.
2. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98:772-776.
3. Calvin AD, Somers VK. Obstructive sleep apnea and cardiovascular disease. Curr Opin Cardiol 2009; 24:516-520.
4. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110:1996-2002.
5. Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Liu J, Harvey-White J, et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 2005; 289:H533-H541.
6. Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, Braulke LJ, et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 2010; 11:273-285.
7. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54:2838-2843.
8. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55:3053-3060.
9. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 2007; 31:692-699.
10. Carley DW, Paviovic S, Janelidze M, Radulovacki M. Functional role for cannabinoids in respiratory stability during sleep. Sleep 2002; 25:391-398.
11. Murillo-Rodriguez E, Blanco-Centurion C, Sanchez C, Piomelli D, Shiromani PJ. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. Sleep 2003; 26:943-947.
12. Jumpertz R, Wiesner T, Bluher M, Engeli S, Batkai S, Wirtz H, et al. Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea: specific role for oleoylethanolamide. Exp Clin Endocrinol Diabetes 2010; 118:591-595.
13. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54:2911-2916.
14. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 2003; 100:1393-1398.
15. Vogeser M, Hauer D, Christina AS, Huber E, Storr M, Schelling G. Release of anandamide from blood cells. Clin Chem Lab Med 2006; 44:488-491.
16. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58:389-462.
17. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975; 18:287-297.
18. Ruilope LM, Despres JP, Scheen A, Pi-Sunyer X, Mancia G, Zanchetti A, et al. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results. J Hypertens 2008; 26:357-367.
19. Niederhoffer N, Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 1999; 126:457-466.
20. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension 1996; 28:682-686.
21. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120:2953-2966.
22. Schroeder C, Batkai S, Engeli S, Tank J, Diedrich A, Luft FC, et al. Circulating endocannabinoid concentrations during orthostatic stress. Clin Auton Res 2009; 19:343-346.
23. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91:3171-3180.
24. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009; 161:715-722.
25. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Batkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension 2008; 52:601-607.
26. Arnardottir ES, Mackiewicz M, Gislason T, Teff KL, Pack AI. Molecular signatures of obstructive sleep apnea in adults: a review and perspective. Sleep 2009; 32:447-470.
27. Gilmartin GS, Lynch M, Tamisier R, Weiss JW. Chronic intermittent hypoxia in humans during 28 nights results in blood pressure elevation and increased muscle sympathetic nerve activity. Am J Physiol Heart Circ Physiol 2010; 299:H925-H931.